Immunological activity in the CNS is largely dependent on an innate immune response and is heightened in diseases, such as diabetic retinopathy, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer’s disease. The molecular dynamics governing immune cell recruitment to sites of injury and disease in the CNS during sterile inflammation remain poorly defined. Here, we identified a subset of mononuclear phagocytes (MPs) that responds to local chemotactic cues that are conserved among central neurons, vessels, and immune cells. Patients suffering from late-stage proliferative diabetic retinopathy (PDR) had elevated vitreous semaphorin 3A (SEMA3A). Using a murine model, we found that SEMA3A acts as a potent attractant for neuropilin-1–positive (NRP-1–positive) MPs. These proangiogenic MPs were selectively recruited to sites of pathological neovascularization in response to locally produced SEMA3A as well as VEGF. NRP-1–positive MPs were essential for disease progression, as NRP-1–deficient MPs failed to enter the retina in a murine model of oxygen-induced retinopathy (OIR), a proxy for PDR. OIR mice with NRP-1–deficient MPs exhibited decreased vascular degeneration and diminished pathological preretinal neovascularization. Intravitreal administration of a NRP-1–derived trap effectively mimicked the therapeutic benefits observed in mice lacking NRP-1–expressing MPs. Our findings indicate that NRP-1 is an obligate receptor for MP chemotaxis, bridging neural ischemia to an innate immune response in neovascular retinal disease.
Neuropilin-1 mediates myeloid cell chemoattraction and influences retinal neuroimmune crosstalk

Agnieszka Dejda,1,2 Gaelle Mawambo,1 Agustin Cerani,1 Khalil Miloudi,2 Zhuo Shao,1 Jean-Francois Daudelin,4 Salix Boulet,4 Malika Oubaha,3 Felix Beaudoin,1 Naoufal Akla,2 Sullivan Henriques,2 Catherine Menard,1 Andreas Stahl,1 Jean-Sébastien Delisle,4 Flavio A. Rezende,2 Nathalie Labrecque,4 and Przemyslaw Sapieha1,2,3

1Department of Biochemistry and Molecular Medicine and 2Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. 3Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada. 4Department of Medicine Microbiology, Infectiology and Immunology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec, Canada. 1University Eye Hospital Freiburg, Freiburg, Germany.

Immune surveillance in the retina, in which an intensified, largely microglial/macrophage immune response is associated with the progression of several sight-threatening diseases, such as diabetic retinopathy, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer’s disease. The molecular dynamics governing immune cell recruitment to sites of injury and disease in the CNS during sterile inflammation remain poorly defined. Here, we identified a subset of mononuclear phagocytes (MPs) that responds to local chemotactic cues that are conserved among central neurons, vessels, and immune cells. Patients suffering from late-stage proliferative diabetic retinopathy (PDR) had elevated vitreous semaphorin 3A (SEMA3A). Using a murine model, we found that SEMA3A acts as a potent attractant for neuropilin-1–positive (NRP-1–positive) MPs. These proangiogenic MPs were selectively recruited to sites of pathological neovascularization in response to locally produced SEMA3A as well as VEGF. NRP-1–positive MPs were essential for disease progression, as NRP-1–deficient MPs failed to enter the retina in a murine model of oxygen-induced retinopathy (OIR), a proxy for PDR. OIR mice with NRP-1–deficient MPs exhibited decreased vascular degeneration and diminished pathological preretinal neovascularization. Intravitreal administration of a NRP-1–derived trap effectively mimicked the therapeutic benefits observed in mice lacking NRP-1–expressing MPs. Our findings indicate that NRP-1 is an obligate receptor for MP chemotaxis, bridging neural ischemia to an innate immune response in neovascular retinal disease.

Introduction

The CNS had long been considered an immune-privileged system, yet it is now clear that the brain, retina, and spinal cord are subjected to complex immune surveillance (1, 2). This is evident in the retina, in which an intensified, largely microglial/macrophage-based immune response is associated with the progression of several sight-threatening diseases, such as diabetic retinopathy (DR) (3–5), age-related macular degeneration (AMD) (6–8), and retinopathy of prematurity (ROP) (9, 10). Together, these retinal diseases account for the principal causes of loss of sight in industrialized countries (6, 11, 12). A common etiology for binding vasoproliferative retinopathies such as DR and ROP is the initial degeneration of retinal microvasculature, followed by ischemic stress on the neuroretina. This triggers a second phase of deregulated and destructive angiogenesis (13). Given this sequence of events and prominent clinical features, the most widely used, current local ocular therapeutic interventions directly target pathological neovascularization yet present a number of nondesirable off-target effects. For example, front-line treatments, such as laser photocoagulation, which ablate ischemic retinal tissue with the aim of reducing production of angiogenic factors, compromise visual field and provoke scotomas. Moreover, given the neuroprotective properties of VEGF, a growing number of neurological and developmental side effects are being attributed to long-term intravitreal anti-VEGFs regimens (4, 11, 14–16). Overcoming these therapeutic limitations or exploring novel pharmacological avenues is therefore required to ameliorate the safety profiles of current interventions. In this regard, there is increasing evidence for the breakdown of the neurovascular unit in proliferative retinopathies (4, 17, 18). In particular, retinal ganglion cells and neurons of the inner nuclear layer that are in intimate contact with degenerating vasculature in DR and ROP (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI76492S1) are subjected to various forms of cellular stress, including ER stress (19), oxidative stress (13), inflammatory stress (18–21), and increased microglial activity (22–25). Whether stressed or damaged central retinal neurons themselves have the propensity to modulate the immune response to reestablish local homeostasis, clear debris (2), or segregate irreparably damaged tissue (17) is unknown and could provide therapeutic insight for designing targeted inhibitors of sterile neuroinflammation.

While a role for mononuclear phagocytes (MPs), such as microglia/macrophages, has been established in proliferative retinopathies (22–25), the local tissue-specific molecular cues and...
The ability to bind at least 2 structurally unrelated ligands (VEGF165 and semaphorin 3A [SEMA3A]) via distinct sites (27–29). While predominantly recognized for its role in neuronal or vascular guidance and as a coreceptor for VEGF165 (30), it has also been described on microglia during vascular anastomosis (31) and recently described in tumor-associated macrophages with roles in vessel maturation (32) and proangiogenic properties (33).

Importantly, the physiological role of myeloid-resident NRP-1 remains unclear, particularly in the context of the CNS. We therefore sought to determine the function of myeloid-resident NRP-1 in the pathogenesis of proliferative retinopathies.

Here, we demonstrate that, via production of SEMA3A and VEGF, the ischemic neural retina has the inherent capacity to modulate the innate immune response by summoning circulating MPs to sites of vascular injury. We provide evidence in both human and animal studies for the critical role of myeloid-resident NRP-1 in the chemotaxis and accretion of MPs in proliferative retinopathies.

Our findings further suggest that current anti-VEGF therapies may in part be effective by reducing destructive ocular inflammation.

**Results**

**NRP-1 identifies a population of MPs that are mobilized secondary to vascular injury.** To determine whether MPs such as microglia or macrophages partake in the vascular pathogenesis associated with proliferative retinopathies, we first carried out FACS analysis on whole mouse retinas to elucidate the kinetics of macrophage/microglial accumulation throughout the evolution of OIR (Figure 1A) (75% oxygen from P7–P12 to induce vaso-obliteration and room air until P17 to attain maximal preretinal neovascularization) (refs. 26, 33, and Figure 1, B, E, and H). Our data revealed significantly higher numbers of retinal macrophage/microglial cells (Gr-1+, F4/80+, CD11b+) cells (gating scheme in Supplemental Figure 2) in OIR at all time points analyzed, including a 36% increase during the vaso-obliterative phase at P10 (P = 0.0004) (Figure 1C), a 63% rise during the neovascular phase at P14 (P < 0.0001) (Figure 1F), and a 172% surge during maximal neovascularization at P17 (P = 0.0006) (Figure 1H). These findings agree with the prevailing notion of microglial involvement in retinal neovascularization (22, 23, 34).

---

**Figure 1.** NRP-1 identifies a population of MPs that are mobilized secondary to vascular injury. (A) Schematic depiction of the mouse model of OIR. Representative FACS plots of Gr-1+/F4/80+/CD11b+ cells (microglia) in retinas collected at (B) P10, (E) P14, and (H) P17 from WT OIR and normoxic (N) control mice. (C, F, and I) The number of retinal microglia was significantly increased in OIR at all points analyzed; n = 7–8 (normoxic and OIR) (total of 28–32 retinas per condition; each “n” comprises 4 retinas). (D, G, and J) A proportional increase in the number of NRP-1+ microglia was observed in OIR retinas; n = 3–5 (normoxic and OIR) (total of 12–20 retinas per condition; each “n” comprises 4 retinas). (K and L) To investigate the role of MP-resident NRP-1, we generated LysM-Cre Nrp1fl/fl mice, which have significantly compromised Nrp1 expression in retinal microglia; n = 3 (WT), n = 4 (LysM-Cre Nrp1fl/fl) (total of 12–16 retinas per condition). (M and O) FACS analysis at P10 and P14 during the proliferative phase of OIR reveals that MP-resident NRP-1 is essential for MP infiltration into the ischemic retina, (N and P) as LysM-Cre Nrp1fl/fl mice did not show an increase in numbers of Gr-1+/F4/80+/CD11b+ cells in OIR at these time points. (Q and R) At P17, MPs infiltrate independent of NRP-1; n = 7–8 (normoxic), n = 7–9 (OIR) (total of 28–36 retinas per condition; each “n” comprises 4 retinas). (S) MP accumulation in the retinas over the course of OIR in WT and LysM-Cre Nrp1fl/fl mice. Data is expressed as fold change relative to control ± SEM. *P < 0.05, **P < 0.001, ***P < 0.0001.

---

**Figure 2.** Retinal NRP-1+ MPs express microglial markers. Representative FACS plots from P14 OIR retinas depicting that (A) 95% (in WT) and (B) 94.7% (in LysM-Cre Nrp1fl/fl) of Gr-1+/F4/80+/CD11b+ cells express high levels of CX3CR1 and intermediate/low levels of CD45 consistent with a microglial phenotype. CX3CR1low and CD45+ cells (A) express NRP-1 in WT retinas and (B) do not express NRP-1 in retinas from LysM-Cre Nrp1fl/fl mice.
Importantly, at each time point investigated, we observed a proportional increase in NRP-1+ MPs in OIR, with a rise of 37% at P10 ($P = 0.0240$) (Figure 1D), 61% at P14 ($P = 0.0196$) (Figure 1G), and 155% at P17 ($P = 0.0058$) (Figure 1J), suggesting that this subpopulation of NRP-1+ MPs was being recruited to the neuroretina during the progression of the disease. For all OIR experiments, weights of mouse pups were recorded (Supplemental Figure 3) to ascertain adequate metabolic health (35).

In order to establish the role of MP-resident NRP-1 in retinopathy, we generated a myeloid-specific knockout of Nrp1 by intercrossing Nrp1-floxed mice with LysM-Cre mice (36), yielding LysM-Cre Nrp1fl/fl progeny. The resulting mice showed an approximately 80% decrease in NRP-1 expression in retinal MPs when compared with that in LysM-Cre Nrp1+/+ littermate controls ($P = 0.0004$) (Figure 1K and L). Of note, mice tested negative for the rd8 mutation of the Crb1 gene (37). LysM-Cre Nrp1fl/fl mice did not show any difference in body weight, size, or open-field activity when compared with littermates throughout the period of experimentation (from P1–P17) (data not shown) and had similar numbers of resident retinal microglia (Supplemental Figure 4).

Remarkably, deletion of NRP-1 on myeloid cells fully abrogated the entry of macrophages/microglia at P10 and P14 OIR (Figure 1, M–P), revealing the critical role for this receptor in MP chemotaxis during the early stages of ischemic retinal injury. At P17, following maximal pathological neovascularization, MP infiltration occurred largely independent of NPR-1 (Figure 1, Q–S). Consistent with a potential microglial identity, the NRP-1-expressing Gr-1+/F4/80+/CD11b+ cells identified above expressed high levels of CX3CR1 and intermediate/low levels of CD45 (Figure 2A). A comparison with spleen-derived cells is provided in Supplemental Figure 5. As expected, in LysM-Cre Nrp1fl/fl retinas, CX3CR1+/CD45- MPs were devoid of NRP-1 (Figure 2B).

NRP-1+ myeloid cells localize to sites of pathological neovascularization in the retina. Confocal images of isolectin B4– (vessel and microglia stain) and NRP-1–stained retinal flat mounts at P14 with budding neovascular tufts in (A) WT and (D) LysM-Cre Nrp1fl/fl mice. (B) High-magnification images reveal colocalization of NRP-1+ microglia (IBA1) with nascent tufts. (D–F) LysM-Cre Nrp1fl/fl mice had fewer MPs and fewer developed tufts. (C and F) Observations were confirmed by 3D reconstruction. White arrows in A point to nascent sprouting tufts. The white arrow in B points to NRP-1+ MPs associated with growing tufts. For all immunohistochemistry images, representative images of 3 independent experiments are shown. Scale bars: 100 μm (A and D); 50 μm (B and E).
in the vitreous of patients suffering from active proliferative DR (PDR). Seventeen samples of undiluted vitreous were obtained from patients suffering from active PDR, and seventeen samples were obtained from control patients with nonvascular pathology. Detailed characteristics of patients are included in Table 1. Control patients presented with nonvascular pathology and showed signs of non-diabetes–related retinal damage, such as tractional tension on vasculature (Figure 5, A and B, white arrows) secondary to fibrotic tissue and macular bulging (Figure 5C). In contrast, all retinas from patients with PDR showed signs of disc (Figure 5D) or preretinal neovascularization (Figure 5F), with highly permeable microvessels (leakage of fluorescent dye) (Figure 5, D and G), microaneurysms (Figure 5, D–G), and fibrous scar tissue, indicative of advanced retinopathy (Figure 5G). In addition, patients showed some evidence of macular edema due to compromised vascular barrier function, including cystoid formation due to focal coalescence of extravasated fluid (Figure 5H).
Consistent with a role in PDR, ELISA-based detection of SEMA3A revealed a 5-fold higher concentration of the protein in the vitreous humors of patients with PDR when compared with that in the vitreous of control patients ($P = 0.0132$) (Figure 5I). Results were confirmed by Western blot analysis on equal volumes of vitreous, where SEMA3A (125- and 95-kDa isoforms) (38, 39) was elevated in patients with PDR (Figure 5J). Thus, upregulation of SEMA3A in the vitreous is induced in diabetic ocular pathology.

**Table 1. Characteristics of patients having undergone vitreous biopsy**

<table>
<thead>
<tr>
<th>Sample</th>
<th>Age (yr)</th>
<th>Diabetes type</th>
<th>Duration (yr)</th>
<th>Retinopathy</th>
<th>Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1</td>
<td>74</td>
<td>NA</td>
<td>NA</td>
<td>MH</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>C2</td>
<td>54</td>
<td>NA</td>
<td>NA</td>
<td>MMD</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>C3</td>
<td>72</td>
<td>NA</td>
<td>NA</td>
<td>ERM</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>C4</td>
<td>77</td>
<td>NA</td>
<td>NA</td>
<td>ERM</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>C5</td>
<td>82</td>
<td>NA</td>
<td>NA</td>
<td>MH</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>C6</td>
<td>62</td>
<td>NA</td>
<td>NA</td>
<td>ERM</td>
<td>ELISA</td>
</tr>
<tr>
<td>C7</td>
<td>65</td>
<td>NA</td>
<td>NA</td>
<td>MH</td>
<td>ELISA</td>
</tr>
<tr>
<td>C8</td>
<td>69</td>
<td>NA</td>
<td>NA</td>
<td>ERM</td>
<td>ELISA</td>
</tr>
<tr>
<td>C9</td>
<td>75</td>
<td>NA</td>
<td>NA</td>
<td>MH/catarract</td>
<td>ELISA</td>
</tr>
<tr>
<td>C10</td>
<td>77</td>
<td>NA</td>
<td>NA</td>
<td>Ret.Det.</td>
<td>ELISA</td>
</tr>
<tr>
<td>C11</td>
<td>69</td>
<td>NA</td>
<td>NA</td>
<td>ERM</td>
<td>ELISA</td>
</tr>
<tr>
<td>C12</td>
<td>68</td>
<td>NA</td>
<td>NA</td>
<td>ERM</td>
<td>ELISA</td>
</tr>
<tr>
<td>C13</td>
<td>81</td>
<td>NA</td>
<td>NA</td>
<td>ERM</td>
<td>ELISA</td>
</tr>
<tr>
<td>C14</td>
<td>70</td>
<td>NA</td>
<td>NA</td>
<td>ERM</td>
<td>ELISA</td>
</tr>
<tr>
<td>C15</td>
<td>65</td>
<td>NA</td>
<td>NA</td>
<td>MH</td>
<td>ELISA</td>
</tr>
<tr>
<td>C16</td>
<td>74</td>
<td>NA</td>
<td>NA</td>
<td>MH</td>
<td>ELISA</td>
</tr>
<tr>
<td>C17</td>
<td>75</td>
<td>NA</td>
<td>NA</td>
<td>MH</td>
<td>ELISA</td>
</tr>
<tr>
<td>PDR1</td>
<td>62</td>
<td>2</td>
<td>13</td>
<td>PDR</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>PDR2</td>
<td>79</td>
<td>2</td>
<td>33</td>
<td>PDR</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>PDR3</td>
<td>73</td>
<td>2</td>
<td>15</td>
<td>PDR</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>PDR4</td>
<td>74</td>
<td>2</td>
<td>10</td>
<td>PDR</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>PDR5</td>
<td>54</td>
<td>1</td>
<td>20</td>
<td>PDR</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>PDR6</td>
<td>60</td>
<td>2</td>
<td>34</td>
<td>PDR</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>PDR7</td>
<td>77</td>
<td>2</td>
<td>34</td>
<td>PDR</td>
<td>WB/ELISA</td>
</tr>
<tr>
<td>PDR8</td>
<td>71</td>
<td>2</td>
<td>10</td>
<td>PDR</td>
<td>ELISA</td>
</tr>
<tr>
<td>PDR9</td>
<td>35</td>
<td>–</td>
<td>–</td>
<td>PDR</td>
<td>ELISA</td>
</tr>
<tr>
<td>PDR10</td>
<td>69</td>
<td>2</td>
<td>40</td>
<td>PDR</td>
<td>ELISA</td>
</tr>
<tr>
<td>PDR11</td>
<td>78</td>
<td>–</td>
<td>5</td>
<td>PDR</td>
<td>ELISA</td>
</tr>
<tr>
<td>PDR12</td>
<td>36</td>
<td>2</td>
<td>–</td>
<td>PDR</td>
<td>ELISA</td>
</tr>
<tr>
<td>PDR13</td>
<td>81</td>
<td>1</td>
<td>30</td>
<td>PDR</td>
<td>ELISA</td>
</tr>
<tr>
<td>PDR14</td>
<td>70</td>
<td>2</td>
<td>30</td>
<td>PDR</td>
<td>ELISA</td>
</tr>
<tr>
<td>PDR15</td>
<td>74</td>
<td>–</td>
<td>35</td>
<td>PDR</td>
<td>ELISA</td>
</tr>
<tr>
<td>PDR16</td>
<td>67</td>
<td>2</td>
<td>30</td>
<td>PDR</td>
<td>ELISA</td>
</tr>
<tr>
<td>PDR17</td>
<td>69</td>
<td>2</td>
<td>2</td>
<td>PDR</td>
<td>ELISA</td>
</tr>
</tbody>
</table>

MH, macular hole; MMD, myopic macular degeneration; ERM, epiretinal membrane; Ret.Det., retinal detachment; WB, Western blot; NA, not applicable; –, not available.

versely, as expected, Vegfr transcripts rose exclusively in the ischemic phase of OIR from P12 to P17 (Figure 6B). Importantly, Vegfr was significantly less induced in LysM-Cre Nrp1fl/fl retinas when compared with WT retinas (minimally increased at P12; $P = 0.0451$) and approximately 55% lower at P14 when compared WT OIR ($P = 0.0003$) (Figure 6B), indicative of a healthier retina.

We next performed laser capture microdissection followed by RT-qPCR on retinal layers in avascular zones to pinpoint the source of Sema3a and Vegfr message in OIR (Figure 4C). Both Sema3a and Vegfr were robustly induced in the ganglion cell layer, with Vegfr also increasing in the inner nuclear layer (Figure 6, D and E). Thus, the source of both ligands is geographically consistent with the localization of retinal MPs (Figures 3 and 4).

**MPs do not proliferate in the retina after vascular injury.** In order to determine whether the noted rise in NRP-1+ MPs was due to an influx from systemic circulation or an increase in MP proliferation within the retina, we investigated local retinal proliferation of these cells. Mice were systemically injected with BrdU at P13 (24 hours prior to sacrifice), and FACS analysis was carried out on retinas (Figure 7A) and spleens (Figure 7B). Within the retinas, Gr-1+/F4/80+/CD11b+ MPs did not show significant proliferation ($P = 0.4708$). Considerably more proliferation was observed in spleens. No significant difference was observed between normoxia and OIR (Figure 7C). The lack of proliferation of MPs in the retinas suggests that the noted accretion of NRP-1+ MPs during retinopathy has a systemic or bone marrow–derived origin, as previously elegantly demonstrated for proangiogenic macrophages (40, 41).

**SEMA3A and VEGF165 mobilize MPs via NRP-1.** In light of the requirement of NRP-1 for myeloid cell mobilization to sites of vascular lesion (Figure 1) as well as the induction of the principal ligands of NRP-1 in retinopathy (Figures 5 and 6) and the likely systemic origin of these cells (Figure 7), we sought to determine the propensity of these cues to provoke chemotaxis of MPs. Primary macrophage cultures were isolated from WT mice and subjected to a Transwell Boyden chamber migration assay. Both SEMA3A (100 ng/ml) ($P < 0.0001$) and VEGF165 (50 ng/ml) ($P = 0.0027$) provoked macrophage chemotaxis to similar magnitudes as positive control MCP-1 (100 ng/ml) ($P < 0.0001$) (Figure 8, A and B). These data were validated by demonstrating that Y-27632, a selective inhibitor Rho-associated coiled coil–forming protein serine/threonine kinase (ROCK), abolished their chemotactic properties. ROCK is downstream of NRP-1 signaling (42) and is known to mediate monocyte migration (43). VEGF migration was partially yet not significantly diminished, suggesting a contribution from alternate receptors such as VEGFR1 as recently reported (33).

Consistent with a role in PDR, ELISA-based detection of SEMA3A revealed a 5-fold higher concentration of the protein in the vitreous humor of patients with PDR when compared with that in the vitreous of control patients ($P = 0.0132$) (Figure 5I). Results were confirmed by Western blot analysis on equal volumes of vitreous, where SEMA3A (125- and 95-kDa isoforms) (38, 39) was elevated in patients with PDR (Figure 5J). Thus, upregulation of SEMA3A in the vitreous is induced in diabetic ocular pathology.

**NRP-1 ligands are induced in the retinal ganglion cell layer during OIR.** To obtain an accurate kinetic profile of expression of the 2 prominent ligands of NRP-1 in proliferative retinopathy, we investigated levels of Sema3a and Vegfr message in the mouse model of OIR. Real-time quantitative PCR (RT-qPCR) on whole retinas revealed that Sema3a was robustly induced in OIR both during the hyperoxic (vasodegenerative) phase at P10 and the ischemic/neovascular stage from P12 to P17 (Figure 6A). The observed induction occurred in both WT and LysM-Cre Nrp1fl/fl retinas. Conversely, as expected, Vegfr transcripts rose exclusively in the ischemic phase of OIR from P12 to P17 (Figure 6B). Importantly, Vegfr was significantly less induced in LysM-Cre Nrp1fl/fl retinas when compared with WT retinas (minimally increased at P12; $P = 0.0451$) and approximately 55% lower at P14 when compared WT OIR ($P = 0.0003$) (Figure 6B), indicative of a healthier retina.
**Figure 5. The NRP-1 ligand SEMA3A is induced in patients suffering from PDR.** Angiographies, funduscopies, spectral-domain optical coherence tomography (SD-OCT), and 3D retinal maps obtained from patients selected for the study. Control patients had nonvascular pathologies and were compared with patients with PDR. Control patients with epiretinal membrane shows signs of non-diabetes-related retinal damage, such as (A and B) tractional tension on vasculature (arrow) secondary to (C) fibrotic tissue (white arrow) and macular bulging (angiography and 3D map). Retinas from patients with PDR have (E) neovascularization (high-magnification image) with (D) highly permeable microvessels, as evidenced by leakage of fluorescent dye (high-magnification image). (F) microaneurysms (arrows in high-magnification image), and (G) fibrous scar tissue (arrow), indicative of advanced retinopathy. (H) Patients with PDR show some evidence of macular edema, including cystoid formation (white arrowhead) due to focal coalescence of extravasated fluid. (I) Vitreous humor analyzed by ELISA shows 5-fold increased levels of SEMA3A protein in patients with PDR. Horizontal bars represent mean concentration of SEMA3A, and dots represent concentrations of individual samples; *P < 0.05. (J) Western blot analysis of equal volumes of vitreous corroborates the increase in SEMA3A (~125 KDa and 95 KDa) in patients with PDR with respect to controls. Scale bars: 1,500 μm (A–G); 300 μm (C and H).
Deficiency in myeloid-resident NRP-1 reduces vascular degeneration and pathological neovascularization in retinopathy. Given the obligate role of NRP-1 in MP infiltration during the early stages of OIR (Figure 1), we next sought to determine the affect of myeloid cell–specific ablation of NRP-1 on the progression of disease. Upon exit from 75% O₂ at P12, LysM-Cre Nrp1 fl/fl mice showed significantly lower levels of retinal vaso-obliteration when compared with those of WT (P = 0.0011) and LysM-Cre Nrp1 +/+ controls (Figure 10, A and B). This may be attributed to lower levels of IL-1β present in the retinas of LysM-Cre Nrp1 fl/fl mice (Supplemental Figure 6). Importantly, at P17, when pathological neovascularization peaks (26), deletion of myeloid-resident NRP-1 profoundly reduced avascular areas (~35% when compared with WT [P < 0.0001] and ~30% compared with LysM-Cre Nrp1 +/+ mice)

Deficiency in myeloid-resident NRP-1 reduces vascular degeneration and pathological neovascularization in retinopathy. Given the obligate role of NRP-1 in MP infiltration during the early stages of OIR (Figure 1), we next sought to determine the affect of myeloid cell–specific ablation of NRP-1 on the progression of disease. Upon exit from 75% O₂ at P12, LysM-Cre Nrp1 fl/fl mice showed significantly lower levels of retinal vaso-obliteration when compared with those of WT (P = 0.0011) and LysM-Cre Nrp1 +/- controls (Figure 10, A and B). This may be attributed to lower levels of IL-1β present in the retinas of LysM-Cre Nrp1 fl/fl mice (Supplemental Figure 6). Importantly, at P17, when pathological neovascularization peaks (26), deletion of myeloid-resident NRP-1 profoundly reduced avascular areas (~35% when compared with WT [P < 0.0001] and ~30% compared with LysM-Cre Nrp1 +/- mice

liposomes (i.e., vehicle control) had no affect on vascular sprouting, but clodronate liposomes reduced microvascular sprouting by approximately 60% (P = 0.0114 for LysM-Cre Nrp1 +/- choroid and P = 0.0007 for LysM-Cre Nrp1 fl/fl choroid) (Figure 9, B–E). To verify whether NRP-1+ macrophages have a propensity to promote angiogenesis, we extracted peritoneal macrophages from LysM-Cre Nrp1 +/- or LysM-Cre Nrp1 fl/fl mice and introduced them into choroid explant cultures that had been treated previously with clodronate liposomes and washed. LysM-Cre Nrp1 +/- macrophages robustly potentiated microvascular sprouting by 50% to 100% when compared with macrophages from LysM-Cre Nrp1 fl/fl mice (P = 0.0068 for LysM-Cre Nrp1 +/- choroid and P = 0.0491 for LysM-Cre Nrp1 fl/fl choroid) (Figure 9, D and E), independent of the genotype of the choroidal explant.

Deficiency in myeloid-resident NRP-1 reduces vascular degeneration and pathological neovascularization in retinopathy. Given the obligate role of NRP-1 in MP infiltration during the early stages of OIR (Figure 1), we next sought to determine the affect of myeloid cell–specific ablation of NRP-1 on the progression of disease. Upon exit from 75% O₂ at P12, LysM-Cre Nrp1 fl/fl mice showed significantly lower levels of retinal vaso-obliteration when compared with those of WT (P = 0.0011) and LysM-Cre Nrp1 +/- (P < 0.0001) controls (Figure 10, A and B). This may be attributed to lower levels of IL-1β present in the retinas of LysM-Cre Nrp1 fl/fl mice (Supplemental Figure 6). Importantly, at P17, when pathological neovascularization peaks (26), deletion of myeloid-resident NRP-1 profoundly reduced avascular areas (~35% when compared with WT [P < 0.0001] and ~30% compared with LysM-Cre Nrp1 +/- mice

liposomes (i.e., vehicle control) had no affect on vascular sprouting, but clodronate liposomes reduced microvascular sprouting by approximately 60% (P = 0.0114 for LysM-Cre Nrp1 +/- choroid and P = 0.0007 for LysM-Cre Nrp1 fl/fl choroid) (Figure 9, B–E). To verify whether NRP-1+ macrophages have a propensity to promote angiogenesis, we extracted peritoneal macrophages from LysM-Cre Nrp1 +/- or LysM-Cre Nrp1 fl/fl mice and introduced them into choroid explant cultures that had been treated previously with clodronate liposomes and washed. LysM-Cre Nrp1 +/- macrophages robustly potentiated microvascular sprouting by 50% to 100% when compared with macrophages from LysM-Cre Nrp1 fl/fl mice (P = 0.0068 for LysM-Cre Nrp1 +/- choroid and P = 0.0491 for LysM-Cre Nrp1 fl/fl choroid) (Figure 9, D and E), independent of the genotype of the choroidal explant.
The Journal of Clinical Investigation

**Research Article**

**Figure 7. NRP-1+ MPs do not proliferate in the retina after vascular injury.** Representative FACS histograms of Gr-1+/F4/80+/CD11b+ cells obtained from (A) retinas and (B) spleens collected at P14 from WT OIR and normoxic control mice injected with BrdU at P13. (C) The number of BrdU+ cells was considerably higher in spleens but did not change significantly between OIR and normoxic mice; $n = 4$ (normoxic), $n = 4$ (OIR) (total of 16 retinas per condition; each “n” comprises 4 retinas). Data are expressed as a percentage of BrdU+ Gr-1+/F4/80+/CD11b+ cells ± SEM.

**Discussion**

Although the contribution of MPs to ocular neovascular diseases such as DR has been established for over a decade, knowledge of the mechanisms by which they are locally recruited to areas of tissue damage and partake in the disease process remains limited. Here, we demonstrate that stressed retinal neurons (19, 21) and neural tissue have the inherent ability to modulate the local innate immune response via unconventional chemotactic agents, such as the classical repulsive guidance cue SEMA3A (21) and vasoattractive and neuroattractive VEGF (Figure 12). We provide evidence that these cues act as potent chemoattractants for NRP-1+ MPs during the early stages of ischemic injury in the retina and contribute to vascular pathology in retinopathy. This neuroimmune paradigm consolidates the stress-induced neurovascular response to injury with an innate immune response. Either genetic ablation of NRP-1 specifically in myeloid cells (LysM-Cre Nrp1"/" mice [$P = 0.0008$]) (Figure 10, C and D). In turn, we observed significant reductions in destructive preretinal neovascularization associated with ischemic retinopathy (~36% when compared with WT [$P = 0.0008$] and ~34% compared with LysM-Cre Nrp1+/+ mice [$P = 0.0013$]) (Figure 10, E and F).

**Therapeutic intravitreal administration of soluble NRP-1 reduces MP infiltration and pathological neovascularization in retinopathy.** To determine the translational potential of our findings, we next used a soluble recombinant mouse NRP-1 (rmNRP-1) (Figure 11A) as a trap to sequester OIR-induced ligands of NRP-1. A single intravitreal injection of rmNRP-1 at P12 lead to a 30% reduction at P14 ($P = 0.0282$) in the number of microglia present in retinas subjected to OIR (Figure 11B). This finding attests to the potency of soluble NRP-1 (1 μl of 500 μg/ml) to compromise microglial mobilization. Intravitreal administration of soluble NRP-1 provoked a significant approximate 40% decrease in pathological preretinal angiogenesis when compared with that of vehicle-injected controls ($P = 0.0025$) (Figure 11, C and D). Together, these data suggest that neutralization of ligands of NRP-1 is an effective strategy to reduce destructive neovascularization in retinopathy.
model serves as a proxy to human ocular neovascular diseases such as DR, which is characterized by a late phase of destructive pathological angiogenesis (54, 55). Upon return to room air, hypoxia-driven neovascularization develops from P14 onward (26). We enucleated eyes at different time points and dissected the retinas for FACS analysis or mRNA analysis as described below. In other experiments, dissected retinas were flat mounted and incubated overnight with fluoresceinated isolectin B4 (1:100) in 1 mM CaCl₂ to determine extent of avascular area or neovascularization area at P17 using ImageJ and the SWIFT-neovascularization method (56).

FACS of digested retinas

Retinas from WT or LysM-Cre Nrp1fl/fl mice were homogenized and incubated in a solution of 750 U/ml DNase I (Sigma-Aldrich) and 0.5 mg/ml DNase I (Sigma-Aldrich) and 0.5 mg/ml. The homogenized retinas were then subjected to FACS analysis as described below. The design of selective antiinflammatory treatments to counter destructive neuroinflammation.

Methods

Animals

C57BL/6 WT mice were purchased from The Jackson Laboratory. LysM-Cre (Lyz2tm1(cre)Ifo/J; no. 004781) and NRP-1–floxed mice (Nrp1tm2Ddg/J; no. 005247) were purchased from The Jackson Laboratory.

O₂-induced retinopathy

Mouse pups (WT or LysM-Cre [The Jackson Laboratory] or LysM-Cre Nrp1fl/fl) and their fostering mothers (CD1, Charles River) were exposed to 75% O₂ from P7 to P12 and returned to room air (53). This model serves as a proxy to human ocular neovascular diseases such as DR, which is characterized by a late phase of destructive pathological angiogenesis (54, 55). Upon return to room air, hypoxia-driven neovascularization develops from P14 onward (26). We enucleated eyes at different time points and dissected the retinas for FACS analysis or mRNA analysis as described below. In other experiments, dissected retinas were flat mounted and incubated overnight with fluoresceinated isolectin B4 (1:100) in 1 mM CaCl₂ to determine extent of avascular area or neovascularization area at P17 using ImageJ and the SWIFT-neovascularization method (56).

FACS of digested retinas

Retinas from WT or LysM-Cre Nrp1fl/fl mice were homogenized and incubated in a solution of 750 U/ml DNase I (Sigma-Aldrich) and 0.5 mg/ml.
Figure 9. NRP-1+ macrophages promote microvascular growth in ex vivo choroid explants. (A) Quantification and representative images of choroid explants isolated from LysM-Cre Nrp1+/+ and LysM-Cre Nrp1fl/fl mice (n = 6; P = 0.018). (B and C) Representative images of choroid explants from (B) LysM-Cre Nrp1+/+ and (C) LysM-Cre Nrp1fl/fl mice following clodronate liposome treatment and subsequent addition of exogenous macrophages (Ma). PBS-Lipo, EGM-2 medium with PBS-filled liposome; Clo-Lipo, EGM-2 medium with dichloromethylenediphosphonic acid disodium salt-filled liposome. (D and E) Quantification of choroidal microvascular sprouting from (D) LysM-Cre Nrp1+/+ and (E) LysM-Cre Nrp1fl/fl mice depicted in B and C. PBS-Liposome, EGM-2 medium with PBS-filled liposome; Clodronate-Liposome. EGM-2 medium with dichloromethylenediphosphonic acid disodium salt-filled liposome. (n = 6, *P < 0.05, **P < 0.01, ***P < 0.001). Scale bars: 500 μm.
Analysis of BrdU incorporation

WT mice subjected to OIR or kept in normoxic conditions were injected intraperitoneally with 5-bromo-2-deoxyuridine (BrdU; Sigma-Aldrich) at the dose of 1 mg per mouse dissolved in PBS at P13.

For analysis of CX3CR1 and CD45 expression, additional extracellular staining was performed using the above-mentioned antibodies supplemented with Alexa Fluor 700 anti-mouse CD45.2 (Biolegend), PE/CY7 anti-mouse Ly-6G/Ly-6C (Gr-1; Biolegend), Pacific Blue anti-mouse F4/80 (Biolegend), 7AAD (BD Biosciences), and anti-mNRP-1 allophycocyanin-conjugated rat IgG2A (R&D Systems) or allophycocyanin-conjugated rat IgG2A isotype control (R&D Systems).

Figure 10. Deficiency in myeloid-resident NRP-1 reduces vascular degeneration and pathological neovascularization in retinopathy. WT, LysM-Cre/Nrp1+/+, and LysM-Cre Nrp1fl/fl mice were subjected to OIR, and retinas were collected at P12 and P17, flat mounted, and stained with isolectin B4. LysM-Cre Nrp1fl/fl mice had (A and B) less vaso-oblitration at P12 and (C and D) reduced avascular areas and (E and F) preretinal neovascularization at P17 compared with both control WT or control LysM-Cre Nrp1fl/fl mice. Results are expressed as percentage of avascular or neovascular area versus the whole retinal area. Horizontal bars represent mean value of percentage, and dots represent individual values; n = 5–19; **P < 0.01, ***P < 0.001.

Scale bars: 250 μm (B, D, and F).

Vitrectomy

All patients previously diagnosed with PDR were followed and operated by a single vitreoretinal surgeon (F.A. Rezende). Control patients underwent surgical treatment for nonvascular pathology (epiretinal membrane or macular hole) by the same surgeon. In an operating room setting, patients underwent surgery under local retro/peribulbar anesthesia. A 5% povidone-iodine solution was used to clean the periocular skin, and topical instillation into the eye and within the cul-de-sac was left in place for 5 minutes. Three-port 25-gauge transconjunctival pars plana vitrectomy was performed through 25-gauge valved cannula (Alcon). Under microscope visualization using a wide-angle viewing system (Resight, Zeiss), undilated vitreous was collected with a 25-gauge vitrector. After vitreous biopsy, the infusion line was opened, and vitrectomy and membrane collagenase D (Roche) for 15 minutes at 37°C with gentle shaking. Homogenates were then filtered with a 70-μm cell strainer and washed in PBS and 3% FBS. Spleen samples were homogenized and incubated with 1 mg/ml collagenase D for 10 minutes at 37°C. Homogenates were washed in PBS and 3% FBS, and the pellets were resuspended and incubated in lysis buffer (10 mM KCHO; 150 mM NH₄Cl; 0.1 mM EDTA) for 5 minutes at room temperature. Cell suspensions (retina or spleen) were incubated with LEAF purified anti-mouse CD16/32 (Biolegend) for 15 minutes at room temperature to block Fc receptors. Cells were then incubated for 30 minutes at room temperature with the following antibodies: FITC anti-mouse/human CD11b (Biolegend), PE/CY7 anti-mouse Ly-6G/Ly-6C (Gr-1; Biolegend), Pacific Blue anti-mouse F4/80 (Biolegend), 7AAD (BD Biosciences), and anti-mNRP-1 allophycocyanin-conjugated rat IgG2A (R&D Systems) or allophycocyanin-conjugated rat IgG2A isotype control (R&D Systems).

Analysis of BrdU incorporation

The staining was performed on the retinal cells from P14 WT mice. Samples were obtained as described above. Extracellular staining was performed as described above (CD45.2 [intermediate/low]; Gr-1; F4/80*, CD11b*; 7AAD). Cells were then fixed with Cytofix/Cytoperm Buffer (BD Biosciences) for 30 minutes and permeabilized with Perm/Wash Buffer (BD Biosciences) for 10 minutes. Next, cells were treated with 300 μg/ml DNAse for 1 hour at 37°C and washed with Perm/Wash Buffer. Intracellular staining of BrdU was performed using anti-BrdU-PE antibodies (Ebioscience) or PE-conjugated mouse IgG1 κ isotype control (Ebioscience) for 25 minutes at 4°C. Cells were then washed in Perm/Wash Buffer and resuspended in PBS and 3% FBS before FACS analysis on a LSRII (BD Biosciences).

BrdU injections

WT mice subjected to OIR or kept in normoxic conditions were injected intraperitoneally with 5-bromo-2-deoxyuridine (BrdU; Sigma-Aldrich) at the dose of 1 mg per mouse dissolved in PBS at P13.
peeling was performed in the usual fashion to treat diabetic vitreous hemorrhage and tractional retinal detachment. This was followed by panretinal endolaser photocoagulation, fluid-air exchange, and intravitreal anti-VEGF injection.

Quantification of SEMA3A protein by ELISA
Vitreous samples were frozen on dry ice immediately after biopsy and stored at -80°C. Samples were centrifuged at 15,000 g for 5 minutes at 4°C prior to analysis. SEMA3A levels were quantified in supernatants using ELISAs following manufacturer’s instructions (USCN Life Science Inc.).

Assessment of SEMA3A protein levels by Western blot
Equal volumes of vitreous fluid (20 μl) from PDR and control patients were assessed by standard SDS-PAGE technique for the presence of SEMA3A (Abcam).

Real-time PCR analysis
RNA was isolated using the GenElute Mammalian Total RNA Mini-prep Kit (Sigma-Aldrich) and digested with DNase I to prevent amplification of genomic DNA. Reversed transcription was performed using M-MLV reverse transcriptase (Life Technologies), and gene expression was analyzed using SYBR Green (Bio-Rad) in an ABI Biosystems Real-Time PCR machine. β-Actin was used as a reference gene.

Immunohistochemistry
For visualization of pan-retinal vasculature, flat-mount retinas were stained with rhodamine-labeled Griffonia (Bandeiraea) Simplicifolia Lectin I (Vector Laboratories Inc.) in 1 mM CaCl₂ in PBS for retinal vasculature and anti-mouse/rat NRP-1 antibody (goat IgG; R&D Systems) and IBA1 (rabbit polyclonal; Wako).

Primary peritoneal macrophages culture
Adult WT or LysM-Cre Nrp1 fl/fl and LysM-Cre Nrp1 +/+ mice were anesthetized with 2% isoflurane in oxygen 2 l/min and then euthanized by cervical dislocation. Then, a small incision in abdominal skin of mouse was performed. Skin was pulled to each size of the mouse, and the peritoneal cavity was washed with 5 ml PBS plus 3% FBS for 2 minutes. Then, the harvested cells were centrifuged for 5 minutes at 100 g, resuspended in medium (DMEM F12 plus 10% FBS and 1% streptomycin/penicillin), and plated. After 1 hour of culture at 37°C under a 5% CO₂ atmosphere, the medium was changed and cells were cultured for the next 24 hours in the same conditions before use in Transwell migration assay.

Transwell migration assay
Migration assays were performed in 24-well plates with 8-μm pore inserts. Primary peritoneal macrophages (5 x 10⁵ cells) resuspended in 200 μl medium (DMEM F12 plus 10% FBS and 1% streptomycin/penicillin) were added to the upper chamber. 800 μl medium, with or without migratory factors, MCP-1 (100 ng/ml), SEMA3A (100 ng/ml), and VEGF 165 (50 ng/ml), was added to the lower chamber. Cells were allowed to migrate through the insert membrane overnight at 37°C under a 5% CO₂ atmosphere. In some experiments, cells were first pre-treated with Y-27632 (Sigma-Aldrich), selective ROCK inhibitor (100 μg/ml), for 1 hour at 37°C. The inserts were then washed with PBS, and nonmigrating cells were swabbed from the upper surface of the insert membrane with cotton buds. Then, the membranes with migrated cells were fixed with 4% paraformaldehyde for 20 minutes, washed twice with PBS, and mounted on the slide. The cells were stained using mounting medium with DAPI (Vector Laboratories Inc.). Then, 9 random fields per each membrane were photographed using an inverted fluorescence microscope at ×20 magnification, and the cells were counted using ImageJ software.

Choroidal explants and microvascular sprouting assay
The ex vivo choroid explant analysis and quantification of microvascular sprouting were performed as described previously (57). Briefly, choroids from LysM-Cre Nrp1<sup>−/−</sup> and LysM-Cre Nrp1<sup>fl/fl</sup> mice (n = 6 for each condition) were dissected shortly after enucleating eyes. After plating segmented choroids into 24-well tissue culture plates and covering with Matrigel (BD Biosciences), samples were treated with EGM-2 medium, EGM-2 medium with PBS filled liposome, or EGM-2 medium with dichloromethyleneephosphonic acid disodium...
Figure 12. Schematic depiction of findings. The schematic illustrates that during ischemic retinopathies, such as diabetes, avascular zones of the retina, ischemic neurons, and neural tissue produce ligands of NRP-1 (SEMA3A and VEGF), which in turn act as potent chemoattractive agents for proangiogenic microglia. The NRP-1+ microglia then partake in the pathogenesis of proliferative retinopathy, RGC, retinal ganglion cell.
salt filled liposome (Sigma-Aldrich). The packaging of liposomes was performed according to ref. 58. Twelve hours later, liposomes containing passenger components were removed from the wells, followed by washing with PBS. Macrophages from primary peritoneal macrophage cultures (from either LysM-Cre Nrp1−/− or LysM-Cre Nrp1fl/fl mice) were added to choroidal explant cultures to investigate the impact of macrophages on microvascular sprouting.

**Soluble recombinant NRP-1**

WT mice subjected to OIR were intravitreally injected with rmNRP-1 from plasmid (29) or R&D Systems at P12.

**Recombinant proteins**

The following recombinant proteins were used: recombinant mouse CCL2/JE/MCP-1 (from *E. coli*) (R&D Systems) concentration used in vitro at 100 ng/ml; recombinant human SEMA3A Fc chimera (from murine myeloma cell line NS0) (R&D Systems) concentration used in vitro at 100 ng/ml; and recombinant human VEGF165 (PeproTech) concentration used in vitro at 50 ng/ml.

**Statistics**

Data are presented as mean ± SEM. We used a 2-tailed Student’s *t* test and ANOVA, where appropriate, to compare the different groups. *P* < 0.05 was considered statistically different. For ELISA, statistical analysis was performed using nonparametric Mann-Whitney test (GraphPad Prism).

**Study approval**

**Human samples.** We obtained approval of human clinical protocols from the Hopital Maisonneuve-Rosemont ethics committee (Ref. CER: 10059), and patients recruited for local core vitreal biopsy sampling afflicted with type 1 or type 2 diabetes mellitus provided written informed consent. The entire procedure was performed as an outpatient procedure in the minor procedure room within the ambulatory clinic of the Department of Ophthalmology at Hopital Maisonneuve-Rosemont. All instruments were opened and handled in a sterile manner. The study conforms to the tenets of the Declaration of Helsinki.

**Animals.** All animal studies were performed according to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Animal Care Committee of the University of Montreal in agreement with the guidelines established by the Canadian Council on Animal Care.

**Acknowledgments**

P. Sapieha holds a Canada Research Chair in Retinal Cell Biology and The Alcon Research Institute Young Investigator Award. This work was supported by operating grants to P. Sapieha from the Canadian Institutes of Health Research (221478), the Canadian Diabetes Association (OG-3-14-4544-PS), and Natural Sciences and Engineering Research Council of Canada (418637). Additional support was obtained from the Fondation Hopital Maisonneuve-Rosemont, Réseau en Recherche en Santé de la Vision du Quebec, and the Fond en Recherche en Optalmologie de l’UdM. A. Stahl is supported by Deutsche Forschungsgemeinschaft (STA 1102/5-1). F. Beaudoin is supported by the Whitman Foundation.

Address correspondence to: Przemyslaw (Mike) Sapieha, Hopital Maisonneuve-Rosemont Research Centre, 5415 Assomption Boulevard, Montreal, Quebec, H3T 2M4, Canada. Phone: 514.252.3400, ext. 7711; E-mail: mike.sapieha@umontreal.ca.
